| 摘要 |
cardiology. SUBSTANCE: invention, in particular, relates to preventing recurrent cardiac infarction in persons not suffering from hypertonic disease. On 16-18th day after the beginning of infarction, patient receives 12,5 mg Atenolol in the morning and 2.5 mg Enap in the evening. In the second week, dose of Atenolol is increased to 12.5 mg in the morning with the evening dose of Enap as before. In the third week, Atenolol and Enap are continued to be administered both in the morning and in the evening in doses 12.5 mg and 2.5 mg, respectively. If hypotonia is not present, in the 4-5th week, morning and evening doses of Atenolol are increased to 25 mg. Such therapy is continued for 2 years combined with simultaneous administration of single 125 mg doses of aspirin and prolonged nitrates in conventional dosages. EFFECT: enhanced efficiency of cardiac infarction prevention. 5 cl, 2 tbl, 4 ex
|
